Belumosudil versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD (ChiCTR) - Oct 16, 2026 - P4 | N=170 | Not yet recruiting | Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
New P4 trial • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dermatology • Fatigue • Graft versus Host Disease • Hepatology • Immunology • Liver Failure • Portal Hypertension • Pruritus • Transplantation
|